Istesso is rethinking how we manage chronic disease. Rather than trying to stop or slow disease progression, we focus on restoring the body’s natural capacity to repair itself and return to health.
Our pioneering approach centers on mitochondrial Complex I modulators, or MCMs, a new class of oral small molecule drugs that repair and regenerate tissue across multiple organs and disease settings. Our lead clinical program, leramistat, is in Phase 2 trials, and we are expanding MCMs to other chronic age-related diseases with a pipeline of assets, each holding blockbuster potential.
"The ability to repair and regenerate damaged tissue offers us the enormous and game-changing potential to rethink how we treat and manage chronic diseases and age-related decline. It’s hard to imagine anything more rewarding and exciting than that"
Leramistat, a first-in-class mitochondrial complex I modulator (MCM),[1],[2] improves muscle...
22nd April 2026
Istesso, the company developing the first oral regenerative medicines, today...
2nd March 2026
Image: Ticio encadenado by Gregorio Martínez (1547–1598) Regenerative medicine promises...
6th January 2026